drugset / Trial / NCT02148107
Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
It is the objective of this MRD trial to investigate pharmacokinetics, pharmcodynamics, safety and tolerability of rising doses BI 691751 over a treatment period of 14 days to support the further clinical development of this LTA4H-inhibitor. Special emphasis will be given to detect potential effects of BI 691751 on heart rate.
Timeline
- Start
- 2014-05
- Primary completion
- 2014-07
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 691751 | Unknown | — | Oral |
Indications
No indication recorded.